Placebo
Drug2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
NCT Number: NCT04250259
The proposed of this randomized, double blinded, placebo-controlled study is to assess the effect of SAMe compared to placebo in patients with alcoholic cirrhosis Child Class A and B. The primary objective of the study is to test relationship between SAMe (S-adenosylmethionine) supplement on liver function. The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 2
Cedars-Sinai Medical Center, Los Angeles, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for patients with alcoholic cirrhosis
Inclusion criteria
for healthy control :
) individuals 18 to 70 years old (2) able to provide informed consent (3) subjects do not consume any alcohol or those who drink < 50 grams per day on average in women and < 80 grams per day on average in men (4) subjects are healthy without underlying acute or chronic medical conditions.
Exclusion criteria
for patients with alcoholic cirrhosis
Exclusion criteria
for all healthy control participants:
2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Time frame: Baseline to end of 24 months
The hypothesis is that SAMe supplement will improve liver function in patients with alcoholic liver disease. The improvement in liver function will lead to the reduction in all-cause mortality in patients with alcoholic cirrhosis in those who receive SAMe supplement when compared to those receiving placebo.
Time frame: baseline to end of 24 months
The function of intestinal permeability will be evaluated by testing serum lipopolysaccharides (LPS) in patients who receive SAMe compared to those who receive placebo. Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide that are bacterial toxins.
Time frame: baseline to 24 months
Cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of mitochondrial DNA in the blood of patients who receive SAMe compared to those who receive placebo.
Time frame: baseline to 24 months
determining Proportion of subjects undergoing liver transplantation in patients who receive SAMe compared to those who receive placebo
Time frame: baseline to 24 months
Proportion of subjects developing new onset hepatocellular carcinoma in patients who receive SAMe compared to those who receive placebo
Time frame: baseline to 24 months
Proportion of subjects with infection/sepsis (other than SBP) in patients who receive SAMe compared to those who receive placebo
Time frame: baseline to 24 months
capture safety-related endpoints by determining proportion of patients with nausea and emesis, proportion of subjects with unexplained diarrhea in patients receive SAMe compared to those who receive placebo.
Time frame: baseline to 24 months
The function of intestinal permeability will be evaluated by testing soluble(s) CD14 in patients who receive SAMe compared to those who receive placebo. sCD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).
Time frame: baseline to 24 months
The function of intestinal permeability will be evaluated by testing soluble(s) CD163 in patients who receive SAMe compared to those who receive placebo. CD163 is an endocytic receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. As a result of ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163).
Time frame: baseline to 24 months
Levels of cellular oxidative stress and/or endoplasmic reticulum (ER) stress will be evaluated by measuring the levels of cytochrome P450 2E1 (CYP2E1) enriched microparticles in patients who receive SAMe compared to those who receive placebo.CYP2E1 is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body.
Time frame: baseline to 24 months
The metabolic profiling of the serum and urine will be collected by those in the study who received the SAMe supplement and will be used as the surrogates for this prediction.
Contact information is provided by the study sponsor or research team.
Indiana University
Other
A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04106518
Alcohol-Induced Disorders, Alcohol-Related Disorders
Angers, France
View Trial DetailsNCT06866496
Alcohol-Induced Disorders, Alcohol-Related Disorders
Hvidovre, Capital Region, Denmark
View Trial DetailsNCT04689152
Alcohol-Induced Disorders, Alcohol-Related Disorders
Bucheon-si, South Korea
View Trial DetailsNCT05093881
Alcohol-Induced Disorders, Alcohol-Related Disorders
Bucheon-si, South Korea
View Trial Details